Menu Search
Equities

E-Therapeutics PLC

3AQ:STU

E-Therapeutics PLC

Actions
  • Price (EUR)0.104
  • Today's Change0.006 / 6.12%
  • Shares traded0.00
  • 1 Year change-26.76%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.

  • Revenue in GBP (TTM)475.00k
  • Net income in GBP-8.27m
  • Incorporated2001
  • Employees38.00
  • Location
    E-Therapeutics PLCFloor 44 Kingdom Street, Paddington CentralLONDON W2 6BDUnited KingdomGBR
  • Phone+44 204 551 8888
  • Fax+44 199 388 0207
  • Websitehttps://www.etherapeutics.co.uk/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.